Evidence map›Paper›PMID 40990474›Full record

ArticleApplied and environmental microbiology2025

A novel homoarginine-containing cyclic peptide pioamide with selective antipseudomonal activity isolated from the nematode symbiont

Yu Imai, Sangkeun Son, Miho Sasaki, Libang Liang, Michael F Gates, Meghan Ghiglieri, Takeshi Shimosato, Chandrashekhar Honrao, Xiaoyu Ma, Jason J Guo and 1 more

Abstract read
In one paragraph

Article in Applied and environmental microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu Imai *Institute for Aqua Regeneration, Shinshu University, Nagano, Japan.ORCID 0000-0001-9853-5115
Sangkeun Son *Department of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.
Miho SasakiDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.
Libang LiangDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.ORCID 0009-0000-6239-9158
Michael F GatesDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.
Meghan GhiglieriDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.
Takeshi ShimosatoInstitute for Aqua Regeneration, Shinshu University, Nagano, Japan.ORCID 0000-0001-8132-1911
Chandrashekhar HonraoDepartment of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Xiaoyu MaDepartment of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Jason J GuoDepartment of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Kim LewisDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.ORCID 0000-0002-1621-7664

Funding

Discovering antimicrobials acting against MDR pathogensR01AI170962 · NIAID · NORTHEASTERN UNIVERSITY · PI LEWIS, KIM · 2022 to 2025
$4.5M
JSPS KAKENHI JP23734491 (23K13867)NIAID NIH HHS R01 AI170962NIH HHS RO1AI170962The Hokuto Bio-science Promotion FoundationThe Nakajima Foundation
6 · The paper itself

Abstract

Gram-negative bacteria harbor an outer membrane that physically protects them from the penetration of antibiotics into the cells. This barrier makes it challenging to develop antibiotics that effectively kill Gram-negative pathogens. The entomopathogenic bacterium IMPORTANCE: The rise of multidrug-resistant Gram-negative bacteria is a growing threat to global public health. Narrow-spectrum antibiotics minimize disruption of the host microbiota and reduce the risk of resistance development in off-target bacteria. In the field of antibacterial discovery, developing compounds effective against

Indexed as

Anti-Bacterial AgentsArginineNematodaPeptides, CyclicPhotorhabdusAnimalsMicrobial Sensitivity TestsPseudomonas aeruginosaSymbiosisAnti-Bacterial AgentsArgininePeptides, Cyclicantibioticnematode symbiontsPhotorhabdusPseudomonas aeruginosa

Identifiers

PMID40990474
PMCPMC12542766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.